BillionToOne Is Solving One of Biotech’s Hardest Problems

Illumina, Inc.

Illumina is a leading NGS platform and consumables provider, and cfDNA diagnostic volume growth is generally supportive. However, the source does not confirm BillionToOne uses Illumina systems or that incremental volumes are material.

TMO is Thermo Fisher Scientific Inc, a Healthcare equity in the Diagnostics & Research industry.

Thermo Fisher could benefit broadly from molecular diagnostics tools, reagents, and lab infrastructure demand, but the read-through is highly indirect.

Content is a YC Startup School talk about building durable startups in the AI era. The actionable market-relevant bits are mostly high-level: (1) intelligence/AI inference is getting much cheaper, (2) moats shift away from “model choice” toward distribution, product loops, data/workflows, and founder execution, and (3) US export restrictions on frontier AI matter. No explicit company mentions or investable calls, so tickers are inferred by theme (AI compute stack, hyperscalers, and export-control-exposed semis).

Talk-level, largely qualitative discussion about AI startups vs Big Tech, with mentions of LLM limits, “world models,” robotics, and continued need for large-scale GPU compute. Actionability is low because there are no concrete catalysts, numbers, or near-term company-specific claims; the most tradable takeaway is a continued AI compute/infra demand narrative (GPU/accelerators, foundry, advanced packaging).

YC talk argues “Physical AI” (AI applied to the physical economy via multimodal sensing/robotics/automation) is the next platform shift; content is conceptual with limited concrete catalysts, but maps to tradable beneficiaries in GPUs/edge compute, industrial automation, and sensor/vision stacks.

Interview-style content about Opencode (open-source Claude Code alternative) claiming rapid adoption (13M MAUs, 20x growth) and heavy token usage, framed around (1) open-source models becoming “good enough,” (2) enterprise adoption of coding agents, (3) model-choice flexibility and token economics, and (4) platform risk illustrated by Anthropic allegedly attempting to block Opencode, which backfired via attention/distribution.

Interview-style content about Photoroom (private) describing how Y Combinator increased founders’ ambition and execution mindset; little concrete product/financial data and no public-company catalysts. Limited direct trading actionability beyond a broad “AI image editing / creator tools / e-commerce enablement” narrative.

YC Startup School talk with Dust co-founder argues no single AI lab will dominate; model-agnostic application/platform layer may be a moat. Notes funding being absorbed by frontier labs, raises small by design, and highlights margin compression at the token/model level, making unit economics challenging for AI apps that resell model tokens.

YC Startup School talk: Supabase grew rapidly by offering an open-source, Postgres-based alternative to Firebase/RDS with very fast time-to-value; claims a $500M round and $10B valuation; positions “open source wins the LLM/agent era” and suggests AI agents are becoming core users. Supabase is private, but narrative has read-through to public cloud, database, and devtool vendors.

Podcast-style discussion with PostHog CEO James Hawkins on startup strategy (ambition as GTM, product expansion, founder mindset) and some broad AI/dev tooling themes (LLMs, “recursive AI loop,” intent data, AI-assisted pull requests). No concrete company-specific news, financials, or tradable catalysts.